Skip to content

Project

Fleming Fund Independent Evaluation Supplier

Antimicrobial resistance (AMR) is a global crisis that has the potential to reverse a century of progress in Public Health. Drug-resistant infections could kill 10 million people across the world every year by 2050 unless urgent action is taken. By this date, they could also cost the world around $100 trillion in lost output: more than the size of the current world economy.

1/12/2016

The Fleming Fund is a £265 million One Health programme funded by the Department of Health and Social Care (DHSC) to help tackle antimicrobial resistance worldwide. The Fund supports countries to generate and use data to tackle AMR through increased country capacity to collect drug resistance data, enable data sharing locally, regionally and internationally, and encourage the use of data to promote the rational use of anti-microbials. 

Itad is the independent evaluation supplier for the Fleming Fund as implemented by Mott MacDonald, the Fund’s managing agent. Our five-year multi-country evaluation works in two distinct phases. Initially, our work will generate real-time learning to inform course correction and adaptation of the programme and increase efficiency, effectiveness, and overall impact. In late 2020, our focus will shift to provide an independent assessment of the Fund’s results and achievements. A key feature of the evaluation is that we will visit each of the 16 countries in our sample (out of the 24 where the Fund operates) on three separate occasions.  

In order to make sure our work is both used and useful, we are working closely with Mott MacDonald and DHSC, to ensure that evaluation considerations are embedded and operationalised across the programme. 

Image © Laboratory. Photo Credit: George Redgrave